南非要求世卫组织调查信变异B.1.1.529 (高度变异,高免疫逃逸性)

贵圈

政府都对党
注册
2014-10-21
消息
32,805
荣誉分数
6,138
声望点数
373

Scientists warn of new Covid variant with high number of mutations​

The B.1.1.529 variant was first spotted in Botswana and six cases have been found in South Africa
Dr Tom Peacock of Imperial College London said the variant ‘could be of real concern’ but may just be an ‘odd cluster’

Dr Tom Peacock of Imperial College London said the variant ‘could be of real concern’ but may just be an ‘odd cluster’. Photograph: Brain Light/Alamy

Ian Sample Science editor
@iansample
Wed 24 Nov 2021 18.30 GMT



Scientists have said a new Covid variant that carries an “extremely high number” of mutations may drive further waves of disease by evading the body’s defences.
Only 10 cases in three countries have been confirmed by genomic sequencing, but the variant has sparked serious concern among some researchers because a number of the mutations may help the virus evade immunity.

The B.1.1.529 variant has 32 mutations in the spike protein, the part of the virus that most vaccines use to prime the immune system against Covid. Mutations in the spike protein can affect the virus’s ability to infect cells and spread, but also make it harder for immune cells to attack the pathogen.
The variant was first spotted in Botswana, where three cases have now been sequenced. Six more have been confirmed in South Africa, and one in Hong Kong in a traveller returning from South Africa.
Dr Tom Peacock, a virologist at Imperial College London, posted details of the new variant on a genome-sharing website, noting that the “incredibly high amount of spike mutations suggest this could be of real concern”.
In a series of tweets, Peacock said it “very, very much should be monitored due to that horrific spike profile”, but added that it may turn out to be an “odd cluster” that is not very transmissible. “I hope that’s the case,” he wrote.

The Delta variant of Sars-CoV-2
Is Delta the last Covid ‘super variant’?
Read more

Dr Meera Chand, the Covid-19 incident director at the UK Health Security Agency, said that in partnership with scientific bodies around the globe, the agency was constantly monitoring the status of Sars-CoV-2 variants as they emerge and develop worldwide.
“As it is in the nature of viruses to mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. Any variants showing evidence of spread are rapidly assessed,” she said.
The first cases of the variant were collected in Botswana on 11 November, and the earliest in South Africa was recorded three days later. The case found in Hong Kong was a 36-year-old man who had a negative PCR test before flying from Hong Kong to South Africa, where he stayed from 22 October to 11 November. He tested negative on his return to Hong Kong, but tested positive on 13 November while in quarantine.
England no longer has a red list to impose restrictions on travellers arriving from abroad. People who are not fully vaccinated must test negative before flying and arrange two PCR tests on arrival. Those who are fully vaccinated need to have a Covid test within two days of landing.
Scientists will be watching the new variant for any sign that it is gaining momentum and spreading more widely. Some virologists in South Africa are already concerned, particularly given the recent rise in cases in Gauteng, an urban area containing Pretoria and Johannesburg, where B.1.1.529 cases have been detected.

An NHS vaccinator administers the Moderna Covid-19 vaccine to a woman at a vaccination centre in London.
Trials begin on Covid booster jab hoped to protect against new variants
Read more

Ravi Gupta, a professor of clinical microbiology at Cambridge University, said work in his lab found that two of the mutations on B.1.1.529 increased infectivity and reduced antibody recognition. “It does certainly look a significant concern based on the mutations present,” he said. “However, a key property of the virus that is unknown is its infectiousness, as that is what appears to have primarily driven the Delta variant. Immune escape is only part of the picture of what may happen.”
Prof Francois Balloux, the director of the UCL Genetics Institute, said the large number of mutations in the variant apparently accumulated in a “single burst”, suggesting it may have evolved during a chronic infection in a person with a weakened immune system, possibly an untreated HIV/Aids patient.
“I would definitely expect it to be poorly recognised by neutralising antibodies relative to Alpha or Delta,” he said. “It is difficult to predict how transmissible it may be at this stage. For the time being it should be closely monitored and analysed, but there is no reason to get overly concerned unless it starts going up in frequency in the near future.”

… as you're joining us from Canada, we have a small favour to ask. Tens of millions have placed their trust in the Guardian’s high-impact journalism since we started publishing 200 years ago, turning to us in moments of crisis, uncertainty, solidarity and hope. More than 1.5 million readers, from 180 countries, have recently taken the step to support us financially – keeping us open to all, and fiercely independent.

With no shareholders or billionaire owner, we can set our own agenda and provide trustworthy journalism that’s free from commercial and political influence, offering a counterweight to the spread of misinformation. When it’s never mattered more, we can investigate and challenge without fear or favour.

Unlike many others, Guardian journalism is available for everyone to read, regardless of what they can afford to pay. We do this because we believe in information equality. Greater numbers of people can keep track of global events, understand their impact on people and communities, and become inspired to take meaningful action.

We aim to offer readers a comprehensive, international perspective on critical events shaping our world – from the Black Lives Matter movement, to the new American administration, Brexit, and the world's slow emergence from a global pandemic. We are committed to upholding our reputation for urgent, powerful reporting on the climate emergency, and made the decision to reject advertising from fossil fuel companies, divest from the oil and gas industries, and set a course to achieve net zero emissions by 2030.
 
还调查个毛啊……大家糊弄糊弄过了的啦
没完没了的变异 没完没了的疫苗
这就是盼着全世界都变非洲
 
人是有韧性的,真正的灾难,还没来呢,
真正的Depression还没到呢。

真正的混乱才刚刚开始。

你就要缴枪投降?
 
以前说mRNA最大优点就是快速针对变异研究新疫苗,到底是吹牛逼还是厂家政治化?还是两者都有
 
第一个mRNA为什么只需要两个月就进入实验?

而针对编译版本的疫苗却在一年以后,尚未开发出来,不用说试验了。

可能性

1. 吹牛了

2. 故意不做新版疫苗,老版还没赚够钱?

3. 故意不做新版疫苗,这样疫情会继续,能赚更多钱

4. 故意不做新版疫苗,好卖药(药物利润可能更高)

5. 。。。。。。。。。。。。。。。。。。。。。。。。。。。。。


第五点,我想想都不寒而栗。也许第一版疫苗研制不是两个月的成果,而是早就做出来的东西。

这任何一点都可以解释,为什么到现在没有针对变异的疫苗。(Delta杀死的人口数,早已经超越原始病毒了)
 
我觉得政府已经慌了,比如土豆突发昨天又要发7.5b ,这尼玛还要加息
 
现在的疫苗是不是不管用了? 免疫逃逸?
 
Delta变了四处吧,就搞得,不能防感染了。只防重症。


The B.1.1.529 variant has 32 mutations in the spike protein

一旦传开了,哈哈,估计疫苗全作废。
 
非洲、日本和印度有让病毒自杀的方法不用,非要强迫价高无效的疫苗。
 
第一个mRNA为什么只需要两个月就进入实验?

而针对编译版本的疫苗却在一年以后,尚未开发出来,不用说试验了。

可能性

1. 吹牛了

2. 故意不做新版疫苗,老版还没赚够钱?

3. 故意不做新版疫苗,这样疫情会继续,能赚更多钱

4. 故意不做新版疫苗,好卖药(药物利润可能更高)

5. 。。。。。。。。。。。。。。。。。。。。。。。。。。。。。


第五点,我想想都不寒而栗。也许第一版疫苗研制不是两个月的成果,而是早就做出来的东西。

这任何一点都可以解释,为什么到现在没有针对变异的疫苗。(Delta杀死的人口数,早已经超越原始病毒了)
第五点真的是太恐怖了。
 
这个小同志很有想法吗!


把日本病毒放到美国,是不是比疫苗强出太多了?

哈哈哈啊哈哈哈哈哈哈哈


又是一个以子之矛攻子之盾!好!

看看有识之士,会不会支持!
 
看来就是第5点了,否则无法解释他们为什么丧心病狂地强迫打高价无效的疫苗,而不用廉价有效的老药。
 
看来就是第5点了,否则无法解释他们为什么丧心病狂地强迫打高价无效的疫苗,而不用廉价有效的老药。
你们在给老共平反。
 
你们在给老共平反。
谁说的,你懂逻辑吗?
即便是SPIKE疫苗早就在研究,

COVID19也可以出现在世界上任何实验室。

只能说明SPIKE这个东西,早就存在了。

SPIKE如何和冠状病毒结合,这才是溯源。
 
谁说的,你懂逻辑吗?
即便是SPIKE疫苗早就在研究,

COVID19也可以出现在世界上任何实验室。

只能说明SPIKE这个东西,早就存在了。

SPIKE如何和冠状病毒结合,这才是溯源。
圆吗?
 
后退
顶部